Testing a new drug combined with chemotherapy for advanced pancreatic cancer

Plain-English translation of NCT05257993 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called combined with one of two standard chemotherapy regimens to treat advanced pancreatic cancer. Researchers want to find the safest and most effective dose of this medication when given alongside chemotherapy, and to see whether it helps shrink tumors. This treatment combines a newer drug with proven cancer drugs to potentially improve outcomes for people with pancreatic cancer that cannot be surgically removed.

Pancreatic cancer is very difficult to treat, especially when it has spread or cannot be removed with surgery. This trial is exploring whether adding this new medication to standard chemotherapy might help patients live longer and have better outcomes.

Do you qualify?

You likely qualify if…

you have been diagnosed with pancreatic cancer that cannot be surgically removed and has either spread to nearby tissues or other parts of your body
you have at least one tumor that can be seen and measured on imaging scans
you are healthy enough to tolerate chemotherapy, with a good performance status and expected to live at least 12 weeks
you have adequate blood counts, kidney function, and liver function based on recent lab tests
you are willing to provide written informed consent and understand what the study involves

You likely don't qualify if…

you have had severe allergic reactions to this medication or standard chemotherapy drugs
you have another type of cancer or serious heart, lung, or blood vessel disease
you have severe nerve damage, chronic diarrhea, or bowel obstruction that would make taking medication difficult
you are currently taking or need to take certain medications that interfere with how this drug works in your body
you have active hepatitis B or C, HIV, or uncontrolled high blood pressure

What participation looks like

You would receive the new medication along with one of two chemotherapy regimens (your doctor will determine which is right for you). The study uses a "dose-finding" approach, which means doctors will start at a lower dose and gradually increase it to find the safest level that still works well. You would visit the clinic regularly for blood tests, imaging scans, and to receive your treatment, and the study will monitor you closely for any side effects. The study is currently recruiting participants and is expected to enroll about 71 people total.

AI-generated summary from trial data · Jul 6, 2026 · Not medical advice

Trial locations(4 sites)

South Korea

Seoul National University Bundang Hospital, Gyeonggi-do

Samsung Medical Center, Seoul

Seoul national university hospital, Seoul

Severance Hospital, Seoul